| Literature DB >> 25669349 |
Elżbieta Szacoń1, Marzena Rządkowska, Agnieszka A Kaczor, Ewa Kędzierska, Antonina Mazur, Sylwia Fidecka, Dariusz Matosiuk.
Abstract
A series of 20 N-substituted derivatives of 1-arylimidazolidyn-2-ylideneurea and products of their cyclization was designed as compounds having double antinociceptive and serotoninergic activity. Ethyl {[(1-arylimidazolidin-2-ylidene)carbamoyl]amino}acetates were prepared from 1-aryl-4,5-dihydro-1H-imidazol-2-amines and ethyl isocyanatoacetate, and then converted with ammonia solution to 2-{[(1-phenylimidazolidin-2-ylidene)carbamoyl]amino}acetamides. Both series of N-substituted derivatives of 1-arylimidazolidyn-2-ylideneureas were subjected to cyclization to respective imidazo[1,2-a][1,3,5]triazines. Chain and cyclic compounds bearing ester moiety affected spontaneous locomotor activity, body temperature of mice as well as showed antinociceptive and serotoninergic activity. Interestingly, their antinociceptive activity was not reversed by naloxone, thus it is not mediated through the opioid system. Chain and cyclic compounds bearing amide moiety were devoid of central nervous system (CNS) activity which may be attributed to unfavorably low lipophilicity (connected with too high polar surface area and too small molecular volume) and poor blood-brain barrier permeation properties.Entities:
Keywords: 1-aryl-4; 5-dihydro-1H-imidazol-2-amines; antinociceptive compounds; central nervous system (CNS) activity; imidazo[1,2-a][1,3,5]triazines
Mesh:
Substances:
Year: 2015 PMID: 25669349 DOI: 10.3109/14756366.2014.965699
Source DB: PubMed Journal: J Enzyme Inhib Med Chem ISSN: 1475-6366 Impact factor: 5.051